Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide that are among the causative agents, which reduce the activity of SOD, CAT, GPX, glutathione-S-transferase, and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients [45]. This evidence concerns the gene HPGDS and breast cancer.